WCA
RETA

Windsor Creek Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Windsor Creek Advisors’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-2,057
Closed -$297K – 214
2020
Q1 		$297K Buy
+2,057
New +$397K 0.11% 130
2019
Q4 		– Sell
-9,138
Closed -$734K – 174
2019
Q3 		$734K Buy
+9,138
New +$775K 0.18% 89

Other funds holding RETA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Windsor Creek Advisors's RETA Position: Q2 2020 in Review

Windsor Creek Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2020, closing a stake of 2,057 shares — an estimated $297K sold.

Windsor Creek Advisors first reported a position in RETA in Q3 2019 and held it in 2 quarters. The position peaked at $734K in Q3 2019. 207 funds tracked by Wall St. Rank hold RETA as of Q2 2020.

  • Windsor Creek Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2020 after selling out during the quarter.
  • Windsor Creek Advisors sold 2,057 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2020, an estimated $297K.
  • Windsor Creek Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2019 and held it in 2 quarters.
  • Windsor Creek Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $734K in Q3 2019.
  • 207 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2020.

Based on Windsor Creek Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.